Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Diseases 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Pain 1Mouth Neoplasms 1Leiomyoma 1Dysmenorrhea 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Colorectal Neoplasms 1

Interventions

Bevacizumab 119Fluorouracil 91Leucovorin 83Cetuximab 83Oxaliplatin 80pembrolizumab 71Irinotecan 67Nivolumab 45Capecitabine 43Specimen Handling 40regorafenib 30trifluridine tipiracil drug combination 29Folfox protocol 29Magnetic Resonance Spectroscopy 27Biopsy 27Panitumumab 26Standard of Care 25HMPL-013 25IFL protocol 20Gemcitabine 20Trifluridine 19Cisplatin 19Blood Specimen Collection 19tislelizumab 17atezolizumab 17Carboplatin 17balstilimab 16Colonoscopy 16encorafenib 15Paclitaxel 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Neoplasms × Naproxen × 1 year × Clear all
NCT05411718 2026-06-01

A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome

M.D. Anderson Cancer Center

Phase 2 Recruiting
40 enrolled
Gastrointestinal

Colorectal Neoplasms, Hereditary Nonpolyposis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡